The vaccine industry

Vaccines

Volumn , Issue , 2008, Pages 37-44

  Douglas, R Gordon ^a   Sadoff, Jerald ^b   Samant, Vijay ^c  

^a Infectious Diseases and Global Health   (United States)

^b Aeras Global TB Vaccine Foundation   (United States)

^c Vical   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893135074     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3611-1.50007-6     Document Type: Chapter

References (15)

1. KS Warren (1986) New scientific opportunities and old obstacles in vaccine development. Proc Natl Acad Sci USA 83 9275-9277.
2. SB Halsted and BG Gellin (1994) Immunizing children: can one shot do it all? In Medical and Health Annual 1994 Chicago: Encyclopedia Britannica
3. J Cohen (2002) Public health: U.S. vaccine Supply falls seriously short. Science 295 1998-2001.
4. G Peter, M des Vignes-Kendrick, TC Eickhoff, et al. (1999) Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee. Pediatrics 104(4 pt 1), 942-950.
5. EK Marcuse, J Braiman, RG Douglas, et al. (1997) for the National Vaccine Advisory Committee. United States vaccine research: a delicate fabric of political and private collaboration. Pediatrics 100 1015-1020.
6. J Gregerson (1987) Vaccine development: the long road from initial idea to product licensure. MM Levin, GC Woodrow, JB Kaspe, GS Cobon (Eds) New Generation Vaccines New York: Marcel Deleker 1165-1183.
7. J DiMasi, R Hansen and H Grabowski (2003) Cost of new drug development. J Health Econ 22 151.
8. Mercer Management Consulting. Testimony on vaccine policy before the U.S. House of Representatives Committee on Commerce, June 15, 1995.
9. ER Berndt and JA Hurvitz (2005) Vaccine advance-purchase agreements for low income countries: practical issues. Health Affairs 24 653.
10. MV Pauley (2005) Improving vaccine Supply and development: who needs what? Health Affairs 24 680.
11. Presentations by GlaxoSmithKline and Sanofi Aventis at ABN Amro Vaccines Conference, June 2006.
12. Authors’ industry experience.
13. World Health Organization web sites http://www.who.int/csr/disease/influenza/manulist/en/index.html http://www.who.int/immunization_standards/quality/contractmanufdb/index.htm
14. Vaccine company Online. Available at: http://www.gsk.com/investors/pp_pipeline_standard.htm http://www.merck.com/finance/pipeline.swf http://en.sanofi-aventis.com/Images/060531_agm_en_tcm24-13014.pdf http://www.wyeth.com/research/pipeline
15. A Pasternak, A Sabow and A Chadwick-Jones (2006) Structural Shift: Promising Yet Challenging New Markets for Vaccines. Mercer Management Consulting